Clinical trials: Diabetes Type I
Non-Insulin-Dependent Diabetes Mellitus
24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
A better glycemic control is associated with less complications (cardiac diseases, blindness, etcetera) for type 2 diabetic patients.
- Trial name
- NCT00318656
- Testing
- rosiglitazone-metformin fixed dose combination, metformin + glimepiride
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1
A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
The primary purpose of this study is to determine if golimumab can preserve beta-cell function in children and young adults with newly diagnosed Type 1 Diabetes (T1D).
- Trial name
- T1GER (NCT02846545)
- Testing
- Golimumab
- Where
- 33 sites in United States
- Volunteers
- 84 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes
Reproducibility and Method Comparison Studies of the Quo-Test™ A1C System and the Quo-Lab A1C Test and CLIA Waiver Study of the Quo-Test™ A1C System
The Quo-Test A1C Analyzer and Reagent Test System (Quo-Test A1C System) are intended for the in-vitro quantitative determination of glycated hemoglobin in whole blood samples obtained from fingerstick or venous samples for…
- Trial name
- NCT01829061
- Where
- 3 sites in United States
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Quotient Diagnostics Limited
Hypercholesterolaemia
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Primary Objectives: To demonstrate the superiority of alirocumab in comparison with placebo in the reduction of calculated low-density lipoprotein cholesterol (LDL-C) in participants with diabetes treated with insulin and with…
- Trial name
- NCT02585778
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
- Where
- 110 sites in United States, Austria and 8 more
- Volunteers
- 517 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The purpose of this trial is to compare the pharmacokinetic properties (the exposure of the trial drug in the body) of different formulations of NN1218.
- Trial name
- NCT01469143
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Novo Nordisk A/S
T1DM - Type 1 Diabetes Mellitus
The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus
The purpose of the investigation is to evaluate the performance of the I3 CGM in Pediatric Patients with Type 1 Diabetes Mellitus (T1DM) according to the FDA's special controls for iCGM.
- Trial name
- NCT05908448
- Testing
- 13 CGM (continuous glucose monitor)
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- Sinocare
Glucose, Low Blood, Glucose, High Blood
Dose Safety Hybrid Closed Loop and Fully Automated Closed Loop Artificial Pancreas Device in CRC
The objective of this study is to test two different operating modes of the latest version of the Dose Safety artificial pancreas system (APS), the Dose Safety Controller (DSC version 2.3), in a population of subjects with type 1…
- Trial name
- NCT03428295
- Testing
- Dose Safety AP system
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dose Safety Inc.
Diabetes, Diabetes Mellitus, Type 1
Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes
This trial is conducted in Europe. The aim of this research is to compare the efficacy and safety of treatment with NPH insulin and insulin detemir.
- Trial name
- NCT00435019
- Testing
- insulin detemir, insulin NPH, insulin aspart
- Where
- 43 sites in Bulgaria, Czechia and 9 more
- Volunteers
- 348 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 1
Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages
The ultimate goal of the PCDIAB project is to develop a bi-hormonal pump (insulin and glucagon) substituting for the pancreas and facilitating tight euglycemic control in patients with T1DM.
- Trial name
- NCT01916265
- Testing
- Glucagon
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Sleep EEG
EEG Changes of type1 Diabetes During Sleep -Insulin Induced Hypoglycemia
Hypoglycaemia is associated with characteristic changes in the EEG with the appearance of slow frequency waves. In a recent study the investigators have shown that these changes can be recorded from subcutaneous electrodes and…
- Trial name
- sleep (NCT01237509)
- Testing
- Hypo device
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- UNEEG Medical A/S
Type 1 Diabetes, Type 2 Diabetes
To Evaluate the Efficacy and Safety of the Insulin Patch Pump System in Patients With Diabetes.
Patients will be enrolled and randomly assigned to either the test group or the control group for short-time intensive insulin therapy in inpatient setting.
- Trial name
- NCT07403565
- Testing
- Insulin Patch Pump System, Minimed 700
- Where
- 5 sites in China
- Volunteers
- 161 people
- Sponsor
- Suzhou Hechun Medical Technology Co., Ltd.
Type 2 Diabetes
A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2…
- Trial name
- TELOS (NCT06972732)
- Testing
- Metformin, Dapagliflozin/Pioglitazone, Dapagliflozin/Sitagliptin
- Where
- South Korea
- Volunteers
- 204 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type 1 Diabetes Mellitus
Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
Primary Objective: To demonstrate similarity in pharmacokinetics (PK) of SAR341402 and NovoLog after 4x4-week periods of alternating administration of SAR341402 and NovoLog compared to 16-week continuous use of NovoLog in…
- Trial name
- GEMELLI X (NCT03874715)
- Testing
- Insulin Aspart SAR341402, Insulin Aspart, Insulin glargine U100
- Where
- 33 sites in United States
- Volunteers
- 210 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study
Primary objective : To evaluate the efficacy (in terms of change in HbA1c readings starting from baseline then after 13 weeks \& at the end of the study which will be after 26 weeks) in subjects with type I diabetes mellitus.
- Trial name
- GLANS (NCT00539448)
- Testing
- insulin glargine, insulin glulisine
- Where
- 4 sites in Bahrain, Kuwait and 2 more
- Volunteers
- 98 people
- Sponsor
- Sanofi
Type 1 Diabetes, Type 2 Diabetes
User Evaluation of the MiniMed 640G Insulin Pump
This four center international study will include two United Kingdom National Health Service centers, and two centers in Melbourne, Australia.
- Trial name
- NCT01991548
- Testing
- MiniMed® 640G Insulin Pump and Guardian® Link Transmitter
- Where
- 4 sites in Australia, United Kingdom
- Volunteers
- 52 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial
A 6-week crossover study will compare PLGS to SAP outcomes in adults and youth > 6 years old with type 1 diabetes (T1D).
- Trial name
- NCT03195140
- Testing
- Predictive Low Glucose Suspend
- Where
- 4 sites in United States
- Volunteers
- 103 people
- Sponsor
- Tandem Diabetes Care, Inc.
Type 1 Diabetes
A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus
This is a single-centre, randomised, double-blind, 4-way crossover, 4-treatment, euglycaemic clamp study in subjects with Type 1 Diabetes Mellitus (T1DM).
- Trial name
- NCT04501107
- Testing
- Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1), Administration of Ready-to-use BioChaperone insulin lispro (IMP2), Administration of US-approved Humalog® (IMP3)
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Adocia
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus
This open-label, multicenter study is designed to investigate the clinical utility and safety of pramlintide treatment in subjects with type 1 and type 2 diabetes who are failing to achieve the desired level of glycemic control…
- Trial name
- NCT00108004
- Testing
- pramlintide acetate
- Where
- 48 sites in United States
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
- Trial name
- NCT07222332
- Testing
- Baricitinib
- Where
- 130 sites in United States, Australia and 18 more
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
This study will look at the treatment effect of DiaPep277 on preservation of beta-cell function, as defined by meal-stimulated secretion of insulin.
- Trial name
- DIA-AID2 (NCT01103284)
- Testing
- DiaPep277
- Where
- 75 sites in United States, Austria and 12 more
- Volunteers
- 475 people
- Sponsor
- Andromeda Biotech Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.